T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity Zhaoming WangMichael S. ChimentiGeorge J. Weiner Original Article Open access 10 June 2021 Pages: 237 - 249
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma Jan BudcziesMartina KirchnerAlbrecht Stenzinger Original Article Open access 14 June 2021 Pages: 251 - 265
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC Yang WangJun NieJian Fang Original Article Open access 15 June 2021 Pages: 267 - 276
Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis Guanfang LiuQi ZhangErxia Shen Original Article 15 June 2021 Pages: 277 - 287
Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement Koen A. MarijtLisa GriffioenThorbald van Hall Original Article Open access 17 June 2021 Pages: 289 - 300
Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis Ruiting YeHan ZengZewei Wang Original Article 21 June 2021 Pages: 301 - 310
Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1 Juntao LiLinqing SunWeichang Chen Original Article 22 June 2021 Pages: 311 - 325
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group Elena FountzilasSofia LampakiDimitrios Bafaloukos Original Article Open access 23 June 2021 Pages: 327 - 337
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma Mamoru HaradaYuichi IidaHirotsugu Uemura Original Article 23 June 2021 Pages: 339 - 352
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody Haiqing NiLei CaoJunjian Liu Original Article 24 June 2021 Pages: 353 - 363
Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion Eiji TakeuchiYoshio OkanoTsutomu Shinohara Original Article Open access 25 June 2021 Pages: 365 - 372
Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis Gilbert LazarusRefael Alfa BudimanIkhwan Rinaldi Original Article 26 June 2021 Pages: 373 - 386
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab Hitomi JoTatsuya YoshidaYuichiro Ohe Original Article 27 June 2021 Pages: 387 - 398
SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma Lu YuanXixi WuLaiyu Liu Original Article Open access 28 June 2021 Pages: 399 - 415
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma Antoine ItalianoPhilippe A. CassierVictor Moreno Original Article Open access 03 July 2021 Pages: 417 - 431
Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial Staffan Holmberg-ThydénInge Høgh DufvaDaniel El Fassi Original Article 04 July 2021 Pages: 433 - 444
Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes M. Alper KursunelEkim Z. TaskiranGunes Esendagli Original Article Open access 06 July 2021 Pages: 445 - 459
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR Takashi KobayashiKatsuhiro ItoHiroyuki Nishiyama Original Article 07 July 2021 Pages: 461 - 471
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody Rama Krishna NarlaHardik ModiKandasamy Hariharan Original Article 10 July 2021 Pages: 473 - 489
Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma Chao WangMin ShiJun Zhang Original Article Open access 13 July 2021 Pages: 491 - 504
Correction to: OSCC cell‑secreted exosomal CMTM6 induced M2‑like macrophages polarization via ERK1/2 signaling pathway Xin PangSha‑sha WangYa‑ling Tang Correction 25 November 2021 Pages: 505 - 506